The assessment of candidate PROTACs in vitro (in cell-based and non-cell-based assays) is generally based on the biology activity against target proteins, which helps to identify the binding affinity, the permeability, the degradation and stability activity, cell cytotoxicity and others. Meanwhile, in vivo experiment is also very important for drug evaluation since they have the potential to provide conclusive insights about the safety assessment of PROTACs and pushed them into clinical trials.
In vitro tests, different kinds of cells and tissues (which may come from humans, animals, micro-organisms or even plants) provide evidence on the target protein activity and function changes caused by PROTACs. While in vivo, evaluation results of candidate molecules are not always uniformly to in vitro data due to long distance transportation, organizational complexity even various barriers like blood-brain barrier and intestinal barrier. Meanwhile, a living organism is more complexity than cells or tissue cultures, and the interaction between PROTACs and functional activities is not easy to evaluated. In addition, animal species are another difficult for PROTACs. Although with similar organization and immune system, sometimes translation from animals to human fail in clinical trials.
In vivo test refers to the experimentation within the whole and living organisms including both animal studies and clinical trials. More comparative studies are needed on the metabolic, inflammatory, immunological and hormonal pathways to establish the reproducibility of results and the optimization of PROTACs. Profacgen offers various in vivo evaluation services for your project with professional scientist team.
Key features of our services:
One-stop platform and experienced technical team.
Meticulous design and transparent operation process.
High data quality and particularly reliable analysis.
Cost-effective pricing and short turnaround times.
Please contact us for more information and individual service.
1. Garattini S, Grignaschi G. (2017). Animal testing is still the best way to find new treatments for patients. European Journal of Internal Medicine, 39, 32–35. doi:10.1016/j.ejim.2016.11.013